Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study

[1] Drożdżal S(2022)Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 Lancet 399 1513-36

[2] Rosik J(2021)An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment Drug Resist Updat 59 100794-23

[3] Lechowicz K(2021)Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms Pharmacol Ther 225 107843-e9

[4] Machaj F(2021)Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports Bmj 375 n2713-7

[5] Szostak B(2022)Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis Ann Med 54 516-62

[6] Przybyciński J(2023)Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients Clin Infect Dis 76 e342-42

[7] Huang K(2023)Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 swab: a real-life study Viruses 15 2180-e33

[8] Zhang P(2020)High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia Clin Rheumatol 39 2095-24

[9] Zhang Z(2020)Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Science 370 eabd4585-33

[10] Youn JY(2021)New onset of autoimmune diseases following COVID-19 diagnosis Cells 10 3592-408

[1] Drożdżal S(2022)Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 Lancet 399 1513-36

[2] Rosik J(2021)An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment Drug Resist Updat 59 100794-23

[3] Lechowicz K(2021)Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms Pharmacol Ther 225 107843-e9

[4] Machaj F(2021)Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports Bmj 375 n2713-7

[5] Szostak B(2022)Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis Ann Med 54 516-62

[6] Przybyciński J(2023)Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients Clin Infect Dis 76 e342-42

[7] Huang K(2023)Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 swab: a real-life study Viruses 15 2180-e33

[8] Zhang P(2020)High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia Clin Rheumatol 39 2095-24

[9] Zhang Z(2020)Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Science 370 eabd4585-33

[10] Youn JY(2021)New onset of autoimmune diseases following COVID-19 diagnosis Cells 10 3592-408